Adicet scores the first hit for gamma-delta
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
Gamma-delta follows financing with consolidation
A new cell therapy approach has, in low-key fashion, attracted financing and the attention of big biopharma.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.